You are here

Merck buys OncoImmune for US$425m to gain Covid drug

file7ccvo7y5g1yp9oarcwx.jpg
Merck agreed to acquire privately held biopharma company OncoImmune for an upfront payment of US$425 million in cash to gain a potential therapy for severe Covid-19.

[NEW JERSEY] Merck agreed to acquire privately held biopharma company OncoImmune for an upfront payment of US$425 million in cash to gain a potential therapy for severe Covid-19.

OncoImmune shareholders will also be eligible for payments based on sales and on the achievement of certain...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes